Cortexyme-B (01167.HK): The first patient in China to receive the combined treatment of the broad KRAS inhibitor JAB-23E73 and chemotherapy for first-line treatment of KRAS-mutant pancreatic cancer in phase Ib/III clinical trials.

DingTalk Finance App News, JSC-B (01167.HK) announced that the company's broad KRAS inhibitor JAB-23E73, in combination with albumin-bound paclitaxel and gemcitabine, has been administered to the first patient in China in a Phase Ib/III clinical trial for first-line treatment of KRAS mutant pancreatic cancer.